News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Strengthens Its European Presence with the Acquisition of TCTC

January 6, 2020

Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle

Read More

Veristat Strengthens Its Regulatory Expertise with the Acquisition of Catalyst Regulatory Services

December 16, 2019

Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors
 Along the Pathway to Market Approval

 

Read More

Veristat Expands Operations into Taiwan

July 23, 2019

Veristat Expands Operations into Taiwan to Support Growing Client Demand for Clinical Trial, Biostatistics and Programming Excellence in the Region

Opens office in Taipei, Taiwan

 

Read More

Veristat Advances Game-Changing Pain and Inflammation Therapy

January 24, 2019

Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. 

Read More

Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals

January 6, 2019

Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding

 

Read More

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

November 7, 2018

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.   The study will run in Canada and is expected to conclude in December 2018.

Read More

Veristat Partners with TRI For Risk-Based Monitoring Technology

November 5, 2018

Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients

 

Read More

Veristat Strengthens Clinical Operations Capabilities - Acquires Topstone Research

October 1, 2018

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma

Read More

Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™

August 20, 2018

Continues Collaboration to Provide Regulatory Submission Support for
Additional Patisiran Submissions

 

SOUTHBOROUGH, MA –  August 20, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. 

Read More

Veristat Congratulates Agios on the FDA Approval of TIBSOVO®

August 16, 2018

 The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation

 

SOUTHBOROUGH, MA –  August 16, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test.

Read More